13 Active Studies

Chronic Urticaria Clinical Trials Near You

Find 13 actively recruiting chronic urticaria research studies near you. Connect with study sites, check eligibility, and explore new treatment options.

13Active Trials
43+Locations
5,924Participants Needed

Recruiting Studies

Advanced Search

Data: ClinicalTrials.gov · Source of record for eligibility and locations

Top Cities for Chronic Urticaria Clinical Trials

Chronic Urticaria clinical trials are recruiting across 43 cities. Here are the cities with the most active studies:

Chronic Urticaria Trial Phases

PHASE2(4 studies)
PHASE3(3 studies)
EARLY_PHASE1(1 study)
PHASE1(1 study)

8 research organizations are sponsoring chronic urticaria trials.

About Chronic Urticaria

Chronic urticaria involves recurring episodes of itchy, red welts (hives) lasting more than six weeks. Chronic spontaneous urticaria (CSU) occurs without an identifiable trigger. Treatment includes antihistamines and biologics like omalizumab.

Clinical trials are advancing new treatments for chronic urticaria. Currently, 13 studies are recruiting a combined 5,924 participants across the United States. Research is being conducted by 8 organizations including Novartis Pharmaceuticals, Sanofi, Celldex Therapeutics and 5 others.

2026 Chronic Urticaria Research Landscape

As of July 2026, the chronic urticaria clinical trial landscape includes 13 actively recruiting studies across 43 cities in the United States. These studies are collectively seeking 5,924 participants, with an average enrollment target of 456 per study.

The research spans multiple phases of development: 4 studies are in PHASE2, 3 studies are in PHASE3, 1 study is in EARLY_PHASE1, 1 study is in PHASE1. The presence of Phase 3 trials indicates that some chronic urticaria treatments are in late-stage testing and may be approaching regulatory review.

Research is being led by 8 different organizations, including Novartis Pharmaceuticals, Sanofi, Celldex Therapeutics, Pfizer, The University of Texas Health Science Center at San Antonio, and 3 others.

Geographically, chronic urticaria trials are most concentrated in Birmingham, Alabama (3 trials); Little Rock, Arkansas (3 trials); Bakersfield, California (3 trials); San Antonio, Texas (3 trials); Glenview, Illinois (3 trials) and 7 other cities.

Featured Chronic Urticaria Studies

Highlighted recruiting studies for chronic urticaria, selected by enrollment size and research scope.

RecruitingNCT07358364

Remibrutinib in Real-world Clinical Practice

Prospective, multi-country, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical p...

Sponsor: Novartis Pharmaceuticals· 3,280 participants· 1 location (Kirksville)
View full study details →
RecruitingNCT07358780

Remibrutinib in Real-world Clinical Practice - a US Sub-study

Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice populat...

Sponsor: Novartis Pharmaceuticals· 505 participants· 1 location (Kirksville)
View full study details →
RecruitingNCT06868212 · PHASE3

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when administered as an add-on treatment to second generation H1-antihi...

Sponsor: Novartis Pharmaceuticals· 400 participants· 10 locations (Birmingham, Litchfield Park, Payson, Phoenix)
View full study details →

Frequently Asked Questions About Chronic Urticaria Clinical Trials

Are there chronic urticaria clinical trials near me?

Yes, there are 13 chronic urticaria clinical trials currently recruiting across 43+ cities in the United States, including Birmingham, Alabama; Little Rock, Arkansas; Bakersfield, California. Browse the studies above to find one at a location convenient for you.

How do I join a chronic urticaria clinical trial?

To join a chronic urticaria clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.

Are chronic urticaria clinical trials free?

Yes, participation in chronic urticaria clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.

What types of chronic urticaria treatments are being studied?

Current chronic urticaria clinical trials are testing a range of approaches across PHASE2 (4 studies), PHASE3 (3 studies), EARLY_PHASE1 (1 study), PHASE1 (1 study). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 8 research organizations.

Is it safe to participate in chronic urticaria clinical trials?

Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.

Data updated July 16, 2026 from ClinicalTrials.gov

About This Data

Data: ClinicalTrials.gov · Source of record for eligibility and locations

Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.

Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.

Page reviewed by the HelloStudys Research Team · Last updated July 16, 2026 · Data from ClinicalTrials.gov